How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most
Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…
CertaraJanuary 26, 2026
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients
This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…
CertaraJanuary 22, 2026
Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy
Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…
CertaraJanuary 22, 2026
The data fragmentation problem holding drug discovery back
Explore how fragmented data across the drug discovery DMTA cycle impedes progress, and discover how…
CertaraJanuary 21, 2026
Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus
Leveraging adaptive clinical trial designs in oncology can accelerate drug development, while following the FDA…
CertaraJanuary 16, 2026
Check and Fix Structures – How to Marvin
Learn how to check and fix chemical structures from this episode of the How to…
CertaraJanuary 16, 2026
